• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety of JAK inhibitors: a real-life multicenter retrospective cohort study
CONCLUSION: Our real-life data confirm that JAKi are effective and carry a low risk of AESI, especially in patients that do not display cardiovascular risk factors at baseline. Our study could not identify differences between molecules and different profiles should be defined in larger prospective cohorts.PMID:37527867 | DOI:10.3899/jrheum.2023-0145
Source: Journal of Rheumatology - August 1, 2023 Category: Rheumatology Authors: Marco Lanzillotta Nicola Boffini Elisa Barone Gilberto Cincinelli Maria Chiara Gerardi Nicoletta Luciano Maria Manara Nicola Ughi Oscar Massimiliano Epis Carlo Selmi Roberto Felice Caporali Lorenzo Dagna Source Type: research

For Your Eyes Only: 007 Tips for the Management of Cardiovascular Risk Factors in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
J Rheumatol. 2023 Apr 15:jrheum.2023-0219. doi: 10.3899/jrheum.2023-0219. Online ahead of print.ABSTRACTPremature atherosclerosis has been observed during the course of different systemic inflammatory diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).1-3 As a result, cardiovascular (CV) events, including myocardial infarction, stroke, heart failure, coronary artery disease, and death, occur 1.65 to 3 times more commonly in patients with AAV as compared to the general population, and the risk appears to be highest in the firs...
Source: Journal of Rheumatology - April 15, 2023 Category: Rheumatology Authors: Jan Willem Cohen Tervaert Source Type: research

Pages: 1  2  3